当前位置： SCI文献检索 > LEUKEMIA RESEARCH期刊下所有文献 > Neurotoxicity of stem cell mobilization chemotherapy with vinorelbine in myeloma patients after bortezomib treatment.

Neurotoxicity of stem cell mobilization chemotherapy with vinorelbine in myeloma patients after bortezomib treatment.

Abstract：

:Vinorelbine chemotherapy with G-CSF stimulation is the standard mobilization regimen in Switzerland for multiple myeloma patients. However, with the increasing use of bortezomib during induction treatment, adding the neurotoxic compound vinorelbine for mobilization may aggravate bortezomib-induced polyneuropathy. In this retrospective single-center study, we aimed to explore vinorelbine mediated neuropathy in 106 consecutive bortezomib pretreated myeloma patients. We confirmed that vinorelbine with G-CSF represents a reliable and effective regimen for mobilization of autologous stem cells. However, the single administration of 35 mg/m(2) vinorelbine added significant neurotoxicity. We found that 24 patients (24%) reported vinorelbine mediated neurotoxicity: Aggravation of bortezomib-induced neuropathy was observed in 17 patients (17%), and vinorelbine mobilization induced first occurrence of polyneuropathy in additional 7 patients (7%). We observed that development of polyneuropathy was not associated with differing survival rates. Finally, affected patients reported polyneuropathy associated disease burden as "very high" in 13% and "high" in 50%. Our data indicate that a single administration of vinorelbine to mobilize autologous stem cells is associated with significant additional polyneuropathy in bortezomib pretreated myeloma patients. The efficacy of vinorelbine mobilization should be balanced against its neurotoxic potential.

journal_name

Leuk Res

journal_title

Leukemia research

authors

Keller S,Seipel K,Novak U,Mueller BU,Taleghani BM,Leibundgut K,Pabst T

doi

10.1016/j.leukres.2015.03.015

subject

Has Abstract

pub_date

2015-07-01 00:00:00

pages

786-92

issue

7

eissn

0145-2126

issn

1873-5835

pii

S0145-2126(15)00086-7

journal_volume

39

pub_type

杂志文章

相关文献

LEUKEMIA RESEARCH文献大全
  • Long-term follow-up of intensive ara-C-based chemotherapy followed by bone marrow transplantation for adult acute lymphoblastic leukemia: impact of induction Ara-C dose and post-remission therapy.

    abstract：:We report single institution outcome of brief, intensive ara-C-based chemotherapy using bone marrow transplantation as primary intensification for untreated adult patients with acute lymphoblastic leukemia (ALL). Overall disease-free and overall survival were inferior to those reported with prolonged chemotherapy mode...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/s0145-2126(01)00175-8

    authors： Sotomayor EM,Piantadosi S,Miller CB,Karp JE,Jones RJ,Rowley SD,Kaufmann SH,Braine H,Burke PJ,Gore SD

    更新日期：2002-05-01 00:00:00

  • PTK7: a new biomarker for immunophenotypic characterization of maturing T cells and T cell acute lymphoblastic leukemia.

    abstract：:Protein tyrosine kinase-7 (PTK7) was recently identified as a surface protein expressed on hematopoietic cells. To determine if PTK7 is a useful biomarker in clinical practice for acute leukemia immunophenotyping and detection, we examined the PTK7 expression in human bone marrow and thymic specimens. Our results show...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2012.07.004

    authors： Jiang G,Zhang M,Yue B,Yang M,Carter C,Al-Quran SZ,Li B,Li Y

    更新日期：2012-11-01 00:00:00

  • A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells.

    abstract：:Anti-MY9 is an IgG2b murine monoclonal antibody selected for reactivity with immature normal human myeloid cells. The MY9 antigen is expressed by blasts, promyelocytes and myelocytes in the bone marrow, and by monocytes in the peripheral blood. Erythrocytes, lymphocytes and platelets are MY9 negative. All myeloid colo...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/0145-2126(84)90001-8

    authors： Griffin JD,Linch D,Sabbath K,Larcom P,Schlossman SF

    更新日期：1984-01-01 00:00:00

  • Adverse prognostic impact of CD36 and CD2 expression in adult de novo acute myeloid leukemia patients.

    abstract：BACKGROUND AND OBJECTIVES:A consecutive series of acute myeloid leukemias (AML) patients was analyzed in conditions which reduce the inter-assay variations (the same flow cytometer, the same observers and the same panel of monoclonal antibodies) in order to investigate the prognostic information provided by flow cytome...

    journal_title：Leukemia research

    pub_type： 杂志文章,多中心研究

    doi：10.1016/j.leukres.2005.02.015

    authors： Perea G,Domingo A,Villamor N,Palacios C,Juncà J,Torres P,Llorente A,Fernández C,Tormo M,Queipo de Llano MP,Bargay J,Gallart M,Florensa L,Vivancos P,Martí JM,Font L,Berlanga J,Esteve J,Bueno J,Ribera JM,Brunet S,

    更新日期：2005-10-01 00:00:00

  • Sustained disease control in transplant-ineligible patients: the role of continuous therapy.

    abstract：:Many patients with multiple myeloma (MM) are elderly (aged >65 years) or unfit, and therefore ineligible for stem-cell transplantation. The novel agents thalidomide, bortezomib, and lenalidomide have shown improved outcomes in these patients. This article discusses the role of continuous therapy in improving patient o...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/S0145-2126(12)70005-X

    authors： Palumbo A,Niesvizky R

    更新日期：2012-11-01 00:00:00

  • Effects of two sex steroids (17beta estradiol and testosterone) on proliferation and clonal growth of the human monoblastic leukemia cell line, U937.

    abstract：:We investigated the effects of two sex steroids (17beta estradiol and testosterone) on five human leukemia cell lines. We observed a statistically significant inhibition of proliferation, dose and time dependent, of the human monoblastic leukemia cell line U937. This inhibition was associated with a dose dependent dec...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/s0145-2126(98)00101-5

    authors： Mossuz P,Cousin F,Castinel A,Chauvet M,Sotto MF,Polack B,Sotto JJ,Kolodie L

    更新日期：1998-11-01 00:00:00

  • Acute promyelocytic leukemia with del(6)(p23).

    abstract：:We report a unique case of de novo acute promyelocytic leukemia (APL) with cryptic 15;17 rearrangements. Cytogenetically, structural rearrangements of the 6p23 region has been reported mainly in secondary leukemia. This patient had a karyotype of 46, XY, del(6)(p23) and no additional chromosomal abnormalities. Molecul...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/s0145-2126(99)00139-3

    authors： Nakase K,Wakita Y,Minamikawa K,Yamaguchi T,Shiku H

    更新日期：2000-01-01 00:00:00

  • Ionic currents in multidrug resistant K562 human leukemic cells.

    abstract：:In this study, the expression and functional characterization of currents through the CFTR (cystic fibrosis transmembrane regulator) and ORCC (outwardly rectifying chloride channels) were determined in wild-type K562 chronic human leukemia cells (K562-WT) and in its resistant counterpart, the vincristine resistant cel...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2005.02.007

    authors： Assef YA,Cavarra SM,Damiano AE,Ibarra C,Kotsias BA

    更新日期：2005-09-01 00:00:00

  • A pilot study of allogeneic cellular therapy for patients with advanced hematologic malignancies.

    abstract：:Allogeneic hematopoietic stem cell transplantation provides curative therapy for some patients with advanced hematologic malignancies. Disease response after allogeneic transplant is, at least in part, mediated by donor immune cells. In this report we describe a cellular therapy using haploidentical peripheral blood s...

    journal_title：Leukemia research

    pub_type： 临床试验,杂志文章

    doi：10.1016/j.leukres.2008.05.015

    authors： Medina DJ,Gharibo M,Savage P,Cohler A,Kuriyan M,Balsara B,Anand M,Schaar D,Krimmel T,Saggiomo K,Manago J,Talty L,Dudek L,Grospe S,Rubin A,Strair RK

    更新日期：2008-12-01 00:00:00

  • Bortezomib in combination with dexamethasone and subsequent thalidomide for newly-diagnosed multiple myeloma: a Chinese experience.

    abstract：OBJECTIVE:Bortezomib-dexamethasone-thalidomide has been reported to be effective in newly-diagnosed multiple myeloma (MM) with an overall response rate of 92% and a CR rate of 18% (Alexanian et al, Hematology 2007;12(3):235-9), but this regimen has not been tested in the Chinese patients. We report here our results tes...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2009.04.006

    authors： Zheng W,Wei G,Ye X,He J,Li L,Wu W,Shi J,Zhang J,Huang W,Xie W,Luo Y,Xue X,Lin M,Huang H,Cai Z

    更新日期：2009-12-01 00:00:00

  • Role of Myc in differentiation and apoptosis in HL60 cells after exposure to arsenic trioxide or all-trans retinoic acid.

    abstract：:Acute promyelocytic leukemia (APL) is highly malignant and frequently expresses the PML-RARalpha (promyelocytic leukemia-retinoic acid receptor-alpha) fusion protein. This fusion protein is targeted by all-trans retinoic acid (ATRA) and arsenic trioxide (As2O3), presently used in APL therapy. We have evaluated effects...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2007.06.021

    authors： Jiang G,Albihn A,Tang T,Tian Z,Henriksson M

    更新日期：2008-02-01 00:00:00

  • Early assessment of treatment response in patients with AML using [(18)F]FLT PET imaging.

    abstract：:Assessment of treatment response in acute leukemia is routinely performed after therapy via bone marrow biopsy. We investigated the use of positron emission tomography (PET) for early assessment of treatment response in patients with acute myeloid leukemia (AML), using the proliferation marker 3'-deoxy-3'-[(18)F]fluor...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2010.06.010

    authors： Vanderhoek M,Juckett MB,Perlman SB,Nickles RJ,Jeraj R

    更新日期：2011-03-01 00:00:00

  • Immunocytochemical investigation of normal and chronic lymphocytic leukaemia lymphocytes reveals unexpectedly frequent reactivity with some myelomonocytic associated antibodies.

    abstract：:Information about the expression of some myelomonocytic markers in lymphocytes of patients with B-CLL is scarce. We studied the CD13, CD14, CD11c and CD68 surface antigens in 42 controls and in 38 patients with B-CLL to detect their possible reactivity. Eighty-nine percent of B-CLL expressed very strongly the CD14 ant...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/0145-2126(92)90177-9

    authors： Woessner S,Florensa L,Besses C,Vilà RM,Gallés C,Palou L,Sabrafen JS

    更新日期：1992-01-01 00:00:00

  • Continuous intravenous infusion of high dose recombinant interleukin 2 for advanced lymphomas--a phase II study.

    abstract：:The prognosis of patients with advanced refractory lymphoma remains poor. We have carried out a Phase II study of continuous high dose intravenous recombinant interleukin 2 alone without LAK cells in this group of patients. Eight patients have so far been treated, 4 with non-Hodgkins lymphoma and 4 with Hodgkins disea...

    journal_title：Leukemia research

    pub_type： 临床试验,杂志文章

    doi：10.1016/0145-2126(91)90053-v

    authors： Lim SH,Worman CP,Callaghan T,Jewell A,Smith MP,Goldstone AH

    更新日期：1991-01-01 00:00:00

  • Increased Rac activity is required for the progression of T-lymphomas induced by Pten-deficiency.

    abstract：:Mutation of the tumor suppressor PTEN results in loss of its PI3-kinase counteracting function. PI3-kinase stimulates tumor formation by PKB/Akt-mediated cell proliferation and prevention of apoptosis. PI3-kinase may also activate Rho-GTPases and their regulatory GEFs to promote invasion. Here we have analyzed the fun...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2007.03.034

    authors： Strumane K,Song JY,Baas I,Collard JG

    更新日期：2008-01-01 00:00:00

  • Acute leukemia, a rare but fatal complication after liver transplantation.

    abstract：:Little information is available about the risk factors and means to improve the survival rate of acute leukemia in a rare but often fatal complication after liver transplantation (LT). We report the development of AML-M2 in one of the 764 patients who underwent liver transplantation at our center, and review the liter...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2009.03.035

    authors： Jiang N,Li H,Wang GS,Zhang J,Zhang JF,Yi SH,Yang Y,Cai CJ,Lu MQ,Chen GH

    更新日期：2009-10-01 00:00:00

  • Production of a negative regulator of IL-3 by bone marrow cells in response to the supernatant of IL-3-producing STIL-3 leukemia cells.

    abstract：:When spleen cells of mice grafted with STIL-3 C5 cells, a leukemic T-cell line producing IL-3, are cultured in vitro, a high IL-3 activity is detectable in the culture supernatant. However, when bone marrow cells of the same grafted mice are cultured under similar conditions, hardly any IL-3 activity is detectable. To...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/0145-2126(92)90035-6

    authors： Sugimoto K,Taniguchi S,Ogata H,Ikehara S,Fujita J,Mori KJ

    更新日期：1992-09-01 00:00:00

  • Immunotherapy in adult acute leukemia.

    abstract：:The treatment of acute myeloid leukemia (AML) did not evolve profoundly in the last decades. Some improvement has been made for acute lymphoblastic leukemia (ALL). Emerging new treatment modalities, such as immunotherapy, are now beginning to be available for acute leukemia, mostly for patients suffering from ALL. Thi...

    journal_title：Leukemia research

    pub_type： 杂志文章,评审

    doi：10.1016/j.leukres.2017.06.011

    authors： Blum S,Martins F,Lübbert M

    更新日期：2017-09-01 00:00:00

  • Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib.

    abstract：:To highlight dasatinib role in the elderly, 125 unselected patients with CP-CML aged >60 years resistant/intolerant to imatinib were retrospectively evaluated. Grade 3-4 haematological and extra-haematological toxicities were reported in 39 (31.2%) and 34 (27.2%) patients; grade 3-4 haematological toxicity was higher ...

    journal_title：Leukemia research

    pub_type： 杂志文章,多中心研究

    doi：10.1016/j.leukres.2011.05.015

    authors： Latagliata R,Breccia M,Castagnetti F,Stagno F,Luciano L,Gozzini A,Ulisciani S,Cavazzini F,Annunziata M,Sorà F,Rossi AR,Pregno P,Montefusco E,Abruzzese E,Crisà E,Musto P,Tiribelli M,Binotto G,Occhini U,Feo C,Vigner

    更新日期：2011-09-01 00:00:00

  • Occupation, hobbies, and acute leukemia in adults.

    abstract：:Occupational and industrial exposures have been implicated in the etiology of leukemia, yet uncertainty remains regarding potential high risk occupations. We examined the associations between self-reported occupations and hobbies and acute leukemia risk using data from 811 cases and 637 controls participating in a cas...

    journal_title：Leukemia research

    pub_type： 杂志文章,多中心研究

    doi：10.1016/j.leukres.2005.03.002

    authors： Terry PD,Shore DL,Rauscher GH,Sandler DP

    更新日期：2005-10-01 00:00:00

  • Expression and function of the calcitonin receptor by myeloma cells in their osteoclast-like activity in vitro.

    abstract：:Malignant plasma cells exert osteoclast-like activity in vitro. We investigated the function of the calcitonin (CT) receptor (R) on myeloma cells from patients and in myeloma cell lines. Primary myeloma cells expressed high CTR levels whereas the cell lines uniformly exposed the CTR-2 variant expressed by osteoclasts....

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2007.07.009

    authors： Silvestris F,Cafforio P,De Matteo M,Quatraro C,Dammacco F

    更新日期：2008-04-01 00:00:00

  • Identification of a novel, tissue-specific ABCG2 promoter expressed in pediatric acute megakaryoblastic leukemia.

    abstract：:ABCG2 encodes a transporter protein that is associated with multidrug-resistant phenotypes in many cancers, including acute myeloid leukemia (AML); high levels of expression are generally associated with a poor prognosis. To better understand how expression of ABCG2 is controlled in pediatric AML, we performed a detai...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2011.05.004

    authors： Campbell PK,Zong Y,Yang S,Zhou S,Rubnitz JE,Sorrentino BP

    更新日期：2011-10-01 00:00:00

  • A phase I study of induction chemotherapy for older patients with newly diagnosed acute myeloid leukemia (AML) using mitoxantrone, etoposide, and the MDR modulator PSC 833: a southwest oncology group study 9617.

    abstract：:Older patients with acute myelogenous leukemia (AML) have overexpression of P-glycoprotein (Pgp+), and this has been shown to correlate quantitatively with therapeutic outcome. Since Pgp-mediated efflux of cytotoxic drugs can be inhibited by the cyclosporine analogue, PSC 833, we investigated the use of this agent wit...

    journal_title：Leukemia research

    pub_type： 临床试验,杂志文章

    doi：10.1016/s0145-2126(00)00024-2

    authors： Chauncey TR,Rankin C,Anderson JE,Chen I,Kopecky KJ,Godwin JE,Kalaycio ME,Moore DF,Shurafa MS,Petersdorf SH,Kraut EH,Leith CP,Head DR,Luthardt FW,Willman CL,Appelbaum FR

    更新日期：2000-07-01 00:00:00

  • Prognostic significance of FLT3 mutations in pediatric non-promyelocytic acute myeloid leukemia.

    abstract：:FLT3 is a receptor tyrosine kinase involved in the survival of hematopoietic stem cells, and mutations of FLT3 have been reported to be of prognostic significance. This is the first study of FLT3 mutations in pediatric non-promyelocytic AML patients that received the same treatment scheme in single institute. FLT3 int...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2004.11.006

    authors： Kang HJ,Hong SH,Kim IH,Park BK,Han KS,Cho HI,Shin HY,Ahn HS

    更新日期：2005-06-01 00:00:00

  • High affinity IL-2 receptors on a Hodgkin's derived cell line.

    abstract：:Hodgkin and Sternberg Reed (H and SR) cells, the putative malignant cells of Hodgkin's disease carry regularly T-cell activation antigens, like CD30 and CD25 (low affinity IL-2 receptor). We have investigated the Hodgkin cell line L540, bearing characteristic markers of H and SR cells for its expression of the low aff...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/0145-2126(90)90107-k

    authors： Tesch H,Herrmann T,Abts H,Diamantstein T,Diehl V

    更新日期：1990-01-01 00:00:00

  • Clinical relevance of soluble HLA-I and beta2-microglobulin levels in non-Hodgkin's lymphoma and Hodgkin's disease.

    abstract：:Plasma levels of beta-2 microglobulin (beta2M), a subunit of the human leukocyte antigen-class I (HLA-I) molecule, correlate negatively with outcome in non-Hodgkin's lymphoma (NHL) and Hodgkin's disease (HD). We examined the clinical relevance of soluble HLA-I (sHLA-I) levels in NHL and HD. Sera from consecutive NHL (...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2006.02.013

    authors： Albitar M,Vose JM,Johnson MM,Do KA,Day A,Jilani I,Kantarjian H,Keating M,O'Brien SM,Verstovsek S,Armitage JO,Giles FJ

    更新日期：2007-02-01 00:00:00

  • Less apoptosis in patients with 5q-syndrome than in patients with refractory anemia.

    abstract：:The WHO classification of hematological malignancies includes 5q-syndrome as a separate category within myelodysplastic syndromes (MDS). Clinically, patients with 5q-syndrome have a milder disease than patients with other MDS. The basis for this difference is not known. Identifying 5q-syndrome can be difficult because...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/s0145-2126(02)00039-5

    authors： Washington LT,Jilani I,Estey E,Albitar M

    更新日期：2002-10-01 00:00:00

  • Enhancement of J6-1 human leukemic cell proliferation by membrane-bound M-CSF through a cell-cell contact mechanism II. Role of an M-CSF receptor-like membrane protein.

    abstract：:We have isolated an M-CSF-like membrane-associated growth factor from human leukemic J6-1 cells that can enhance the growth and colony formation of J6-1 cells in vitro. Indirect evidence suggests that this membrane-associated M-CSF-like growth factor may do so by stimulating a corresponding receptor co-expressed on th...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/s0145-2126(97)00135-5

    authors： Wu KF,Rao Q,Zheng GG,He ZH,Ying HG,Song YH,Chen BD

    更新日期：1998-01-01 00:00:00

  • Erythropoietin.

    abstract：:The remarkable capacity of the bone marrow to compensate for blood loss and for reduced atmospheric oxygen tension has been found to be mediated by a renal hormone, named erythropoietin. It is produced by peritubular interstitial cells in response to renal hypoxia, but molecular engineering has permitted large scale p...

    journal_title：Leukemia research

    pub_type： 杂志文章,评审

    doi：10.1016/0145-2126(90)90094-p

    authors： Erslev AJ

    更新日期：1990-01-01 00:00:00

  • Prolymphocytoid variants of chronic lymphocytic leukaemia: an immunological and morphological survey.

    abstract：:Of 417 cases of chronic lymphocytic leukaemia (CLL) examined morphologically, 346 (83%) showed low (less than 10%) numbers of cells with prolymphocytoid (PLC) morphology. Immunological studies in 267 of these cases, with particular reference to membrane surface immunoglobulin (SIg) densities and FMC7 expression, revea...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/0145-2126(87)90018-x

    authors： Scott CS,Limbert HJ,Roberts BE,Stark AN

    更新日期：1987-01-01 00:00:00